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Abstract In this study we present the synthesis and some
pharmacological properties of fourteen new analogues of
neurohypophyseal hormones conformationally restricted in
the N-terminal part of the molecule. All new peptides were
substituted at position 2 with cis-1-amino-4-phenylcyclo-
hexane-1-carboxylic acid (cis-Apc). Moreover, one of the
new analogues: [cis-Apc2, Val4]AVP was also prepared in
N-acylated forms with various bulky acyl groups. All the
peptides were tested for pressor, antidiuretic, and in vitro
uterotonic activities. We also determined the binding
affinity of the selected compounds to human OT receptor.
Our results showed that introduction of cis-Apc2 in position
2 of either AVP or OT resulted in analogues with high
antioxytocin potency. Two of the new compounds,
[Mpa1,cis-Apc2]AVP and [Mpa1,cis-Apc2,Val4]AVP, were
exceptionally potent antiuterotonic agents (pA2 = 8.46 and
8.40, respectively) and exhibited higher affinities for the
human OT receptor than Atosiban (Ki values 5.4 and
9.1 nM). Moreover, we have demonstrated for the first time
that N-terminal acylation of AVP analogue can improve its
selectivity. Using this approach, we obtained compound
Aba[cis-Apc2,Val4]AVP (XI) which turned out to be a
moderately potent and exceptionally selective OT antago-
nist (pA2 = 7.26).
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SIADH Syndrome of inappropriate antidiuretic
hormone hypersecretion
Introduction
The neurohypophyseal hormones, arginine vasopressin
(AVP) and oxytocin (OT), are cyclic nonpeptides which
differ from each other only by two of nine amino acids
residues (Fig. 1). Main physiological roles played by AVP
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are the regulation of water balance, the control of blood
pressure, and the secretion of adrenocorticotropin hormone
(ACTH) (Barberis et al. 1998, 1999). Another neurohy-
pophyseal hormone, OT is classically associated with
female reproduction (lactation and parturition) (Gimpl and
Fahrenholz 2001; Lee et al. 2009).
Both hormones are synthesized as pre-prohormones in
the magnocellular cells of the hypothalamic supraoptic
(SON) and paraventricular nuclei (PVN) and secreted as
mature active peptides from the posterior pituitary gland
into the circulation (Zing et al. 1998; Acher 1993). More-
over, they are released into the central nervous system and
act as neuromodulators and neurotransmitters (Landgraf
and Neumann 2004). Arginine vasopressin was reported to
primarily regulate typical male social behaviours (vocal
communication, aggression, and paternal care) (Goodson
and Bass 2001). Oxytocin was shown to be mainly
involved in maternal behaviour (Insel and Fernald 2004).
Moreover both neuropeptides modulate a wide variety of
other behaviours, including social recognition, learning,
stress, anxiety and depression (Bielsky and Young 2004;
Caldwell et al. 2008; Frank and Landgraf 2008).
The AVP and OT receptor family consists of four sub-
types of receptors: V1A, V1B, V2, and OTR. All these
receptors belong to the large family of G protein-coupled
receptors (GPCRs) and mediate different pharmacological
effects of the hormones. V1A receptors are expressed in
many body tissues (including vascular smooth muscles,
liver, kidney, platelets, spleen) and modulate the vaso-
pressor actions of AVP, gluconeogenesis, and platelet
aggregation (Zingg 1996). V1B receptors present in the
pituitary, pancreas and adrenals mediate the ACTH-release
from the anterior pituitary gland (Jard et al. 1987). More-
over, both V1A and V1B receptors were found in brain,
where they are involved in higher brain functions
(Landgraf and Neumann 2004; Hernando et al. 2001; Frank
and Landgraf 2008). V2 receptors, located in the renal
tubule and particularly the collecting ducts, mediate anti-
diuretic responses to AVP (Zingg 1996). OT is involved in
the control of labor, milk ejection and many social and
behavioral functions via interaction with its receptors
(OTR) expressed in the uterus, mammary glands, and some
regions of the central nervous system (Zingg 1996; Gimpl
and Fahrenholz 2001). The neurohypophyseal hormones
receptors show a high degree of homology (35–50% of
sequence identity) (Wheatley et al. 1993). This, along with
the similar structure of both hormones, may be a reason for
the overlap of pharmacological profiles of OT and AVP.
Arginine vasopressin is essential for osmotic and car-
diovascular homeostasis and impairment of its synthesis,
secretion or metabolism causes some serious clinical dis-
orders including diabetes insipidus, SIADH, congestive
heart failure (Verbalis 2003; Goldsmith 2006). Consider-
able progress has been made in designing specific AVP
analogues in order to treat those disorders (Manning et al.
2008). For example, the V2 agonist 1-deamino-8-D-arginine
vasopressin (dDAVP, trade name Desmopressin) is used in
patients with central diabetes insipidus to reduce urine
production and water loss (Vande Walle et al. 2007).
Desmopressin is, however, far from being an ideal medi-
cation because it is more potent V1B agonist than a V2
agonist in humans (Saito et al. 1997). On the other hand, in
the recent years, there has been increasing interest in OT
receptor antagonists because of their potential therapeutic
value as tocolytic compounds (Romero et al. 2000). Of the
many OT antagonists described to date, only one, Atosiban
(d[D-Tyr(Et)2,Thr4]OVT, trade name Tractocile) has been
approved (in Europe) for the treatment of preterm labor
(Vatish and Thornton 2002). Unfortunately, it is highly
non-selective for OT receptors versus AVP V1A receptors
(Manning et al. 1995). Parallel to the development of
potent and selective peptide agonist and antagonists, the
research of non-peptide agonists and antagonists was car-
ried out. Despite the impressive efforts that have been
devoted to the synthesis of many non-peptide analogues,
only one vasopressin V2/V1 antagonist and one vasopressin
V2 antagonist have been approved by the FDA for clinical
use (Manning et al. 2008, 2010). Thus the design of neu-
rohypophyseal hormones analogues that selectively interact
with appropriate receptors is still a matter of interest.
Many research groups investigate potential strategies to
develop potent and selective analogues of AVP and OT.
Generally, it has been reported that the conformation of the
N-terminal part of neurohypophyseal hormones analogues
is crucial for their pharmacological activity (Lebl 1987;
Manning and Sawyer 1993). For example, replacement of
Tyr2 with bulky or sterically restricted substituents is
favorable for generation of effective antagonistic analogues
(Manning et al. 2005). Also, in our laboratory we have
shown that such an approach could result in analogues with
very interesting pharmacological properties (Kowalczyk
et al. 2006; Derdowska et al. 2005). In 2004, we described
the synthesis and some pharmacological properties of new
AVP analogues having 1-aminocyclohexane-1-carboxylic
acid (Acc, also known as Ac6c) in position 2 (Kowalczyk
Fig. 1 Amino acid sequence of arginine vasopressin (AVP) and
oxytocin (OT)
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et al. 2004). This modification resulted in four highly
potent antidiuretic agonists ([Mpa1,Acc2]AVP, [Acc2,
Val4]AVP, [Mpa1,Acc2,D-Arg8]VP, and [Mpa1,Acc2,
Val4,D-Arg8]VP) with different pressor and uterotonic
activities. Later, we showed that introduction of 3,3-
diphenyl-L-alanine (Dip) or its D-enantiomer (D-Dip) into
position 2 of AVP and some of its analogues resulted in
compounds having strikingly different biological properties
in comparison with those of the parent hormone (Kwiat-
kowska et al. 2009). Their antidiuretic activity was pre-
served and prolonged, while their uterotonic activity was
transformed into antioxytocic one and the effect on blood
pressure was eliminated. Moreover, four of new com-
pounds, [Mpa1,D-Dip2]AVP, [Mpa1,D-Dip2,Val4]AVP, [Mpa1,
D-Dip2,D-Arg8]VP, and [Mpa1,D-Dip2,Val4,D-Arg8]VP, were
exceptionally potent antidiuretic agents with significantly
prolonged activities. Our more recent study reported a
series of AVP analogues substituted in position 2 with a-2-
indanylglycine or its D-enantiomer (Igl or D-Igl, respec-
tively) (Kwiatkowska et al. 2010). Those compounds were
moderate or potent OT antagonists and practically did not
interact with V1A and V2 receptors. It is worth to empha-
size that only a single modification of position 2 of AVP
with Igl was sufficient to obtain selective and potent anti-
oxytocic agent.
Continuing our efforts to obtain potent and selective
analogues of neurohypophyseal hormones we investigated
the effectiveness of steric restrictions and bulky substitu-
ents in the N-terminal part of the AVP and OT molecules.
We decided to check how substitution of position 2 with
bulky cis-1-amino-4-phenylcyclohexane-1-carboxylic acid
(cis-Apc, see Fig. 2a) would reflect in the values of bio-
logical potency of the analogues. The cis-Apc differs from
1-aminocyclohexane-1-carboxylic acid (Acc, Fig. 2a) pre-
viously used in our laboratory (Kowalczyk et al. 2004;
Jastrze˛bska et al. 2003) by the presence of a phenyl moiety
and was chosen in order to find out how the enlargement of
the side chain and change of its character for aromatic one
will influence the activity of resulting analogues. Fourteen
new analogues of neurohypophyseal hormones have been
designed and their structures are summarized in Fig. 3.
First, seven analogues of AVP and its derivatives having
additional substitutions (Cpa1, Mpa1 and/or Val4 and/or
D-Arg8) were prepared (I–VII). Next, four N-acylated
analogues of the most interesting analogue [cis-Apc2,
Val4]AVP (III) were synthesized (VIII–XI). These ana-
logues were obtained by acylation of the N-terminus of the
above peptide with 1-adamantanecarboxylic acid (Aca),
4-tert-butylbenzoic acid (t-Bba), 4-hydroxybenzoic (Hba),
and 4-aminobenzoic acid (Aba), see Fig. 2b). The third
group of analogues was designed by cis-Apc2 substitution
at position of OT, [Mpa1]OT, and [Cpa1]OT (XII–XIV).
Materials and methods
Materials
All solvents and reagents were obtained from commercial
suppliers and used without further purification. All the
Fig. 2 a Structure of unnatural
amino acid cis-Apc and for
comparison Acc b structure of
bulky acyl groups used in the
present study
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amino acid derivatives were purchased from NovaBio-
chem, except Fmoc-cis-Apc and Boc-cis-Apc, which were
provided by NeoMPS. Mpa(Trt) was obtained as described
for Cys(Trt) (Bodanszky et al. 1984) using 3-mercapto-
propionic acid instead of L-cysteine hydrochloride. Cpa
(Mob) was synthesized using a procedure described in the
literature (Rekowski and Lammek 1987). High-performance
liquid chromatography was carried out on a Waters (ana-
lytical and semi-preparative) chromatograph equipped with
a UV detector (k = 226 and 254 nm). The purity of the
peptides was determined on Vydac C18 or Hypersil ODS C18
or Hypersil BDS C18 column (5 lm, 4.6 9 250 mm). The
following solvent systems were used: [A] 0.1% aqueous
TFA, [B] acetonitrile/0.1% aqueous TFA (80:20 v/v). Semi-
preparative HPLC was carried out using a Waters C18 col-
umn (15 lm, 100 A˚´ , 7.8 9 300 mm). The mass spectra
of the peptides were recorded on a MALDI TOF mass
spectrometer.
Peptide synthesis and purification
All the peptides, except analogues VII and XIV, were
obtained manually by solid-phase synthesis (scale
150 lmol) on a polystyrene resin—TentaGel S RAM (Rapp
Polymere, capacity 0.23 mmol/g), according to standard
coupling procedures and Fmoc/But strategy (Fields and
Noble 1990). Analogues VIII–XI were additionally cou-
pling with bulky acetyl groups (Fmoc-Aba, Aca, t-Bba, Hba)
in the final step of synthesis. For protection of the side chain
functionalities, Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-
Cys(Trt), Fmoc-Arg(Pbf) and Fmoc-D-Arg(Pbf) were used.





HOAt) as coupling agents in the presence of NMM in
mixture of DMF/NMP (1:1 v/v) (Zimmer et al. 1992;
Sabatino et al. 2003). The couplings after Fmoc-cis-Apc
were mediated by DMTMM in the presence of DIPEA in
the NMP (Kunishima et al. 1999). In most cases, the Fmoc-
amino acids and acetyl groups were coupled at a threefold
excess for 2.5 h at room temperature. The completeness of
reaction was monitored by the Kaiser test (Kaiser et al.
1970) or chloranil test (Christensen 1979). Recoupling
was performed when the test was positive. The Fmoc
groups were removed by treatment with 20% piperidine
in DMF for 5 and 10 min. Cleavage of peptide-linker bond
and removal of the side chain protecting groups were
accomplished using solution of TFA:H2O:TIS:PhOH
(9.0:2.5:2.5:5.0) in 3 h at room temperature. The solutions of
the released peptides were filtered and evaporated in vacuo to
a volume of about 1 mL. Then the peptides were precipitated
with diethyl ether to afford crude products. Analogues V, XII
synthesized using an Fmoc strategy was obtained in very low
yield, and we resynthesized them by Boc chemistry.
Peptides V, VII, XII, and XIV were synthesized man-
ually using Boc chemistry on a methoxybenzhydryl resin
(MBHA resin, Senn Chemicals AG, 1% DVB, 200–400
mesh, 0.67 mmol/g) on a scale of 200 lmol according to
standard procedures, using in situ neutralization (Schn}olzer
et al. 1992). For protection of side chain functionalities,
Boc-Arg(Tos), Boc-D-Arg(Tos), Boc-Cys(Mob), Cpa(Mob)
were used. Fully protected peptide resin was synthesized
according to standard procedures involving (i) deprotection
steps 33% TFA/DCM in the presence of anisole (1%), 5
and 10 min; (ii) neutralization with 10% TEA/DCM, 5 and
10 min; (iii) couplings of Boc-amino acid; 3 h at room
temperature. In most cases, the amino acids were coupled
at threefold excess using TBTU/HOBt/NMM in the mix-
ture of DMF/NMP (1:1 v/v), and if necessary amino acid/
HATU/HOBt/NMM (1:1:1:2) in mixture of DMF/NMP
(1:1 v/v) for recoupling steps. After 3 h coupling time, the
Kaiser test (Kaiser et al. 1970) or chloranil test (Christensen
1979) was performed to estimate the completeness of the
reaction. After completion of the synthesis, the protected
peptidyl or acylpeptidyl resins were treated with 10 mL of
liquid hydrogen fluoride (HF) containing 1 mL of anisole at
-70 C and stirred for 60 min at 0C (Stewart 1984). After
removal of HF and anisole in vacuo, the mixture was washed
successively with anhydrous diethyl ether, then with acetic
acid and the solution was diluted with methanol.
The formation of the disulfide bond (cyclization) was
carried out with a 0.1 M I2 a solution of methanol and
Y - X1 - X2 - Phe - X3 - Asn - Cys - Pro - X4 - Gly - NH2  (AVP ) 
where: 
Y = H X1= Cys    X2 = cis-Apc  I 
 X1= Mpa   X2 = cis-Apc  II 
Y = H X1= Cys    X2 = cis-Apc X3 = Val             III 
 X1= Mpa   X2 = cis-Apc X3 = Val             IV 
Y = H X1= Cys    X2 = cis-Apc X4 = D-Arg         V 
 X1= Mpa   X2 = cis-Apc X4 = D-Arg         VI 
 X1= Cpa  X2 = cis-Apc  VII 
Y = Aca    X1= Cys    X2 = cis-Apc X3 = Val             VIII 
Y = t-Bba X1= Cys    X2 = cis-Apc X3 = Val             IX 
Y = Hba    X1= Cys    X2 = cis-Apc X3 = Val             X 
Y = Aba    X1= Cys    X2 = cis-Apc X3 = Val             XI 
Y - X1 - X2 - Ile - Gln - Asn - Cys - Pro - Leu - Gly - NH2  (OT) 
where: 
Y = H X1= Cys    X2 = cis-Apc  XII 
 X1= Mpa   X2 = cis-Apc  XIII 
 X1= Cpa X2 = cis-Apc  XIV 
Fig. 3 Structure of the new vasopressin and oxytocin analogues
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acetic acid using a standard procedure (Flouret et al. 1979).
The solvents were evaporated under reduced pressure and
the resulting materials were dissolved in water, frozen and
lyophilized to give the final crude oxidized products. The
crude compounds were desalted on a Sephadex G-15 col-
umn, and eluted with aqueous acetic acid (30%) at a flow
rate of 3 mL/h. After freeze-drying, the fractions com-
prising the major peak were purified by semi-preparative
HPLC (Waters Corporation, Milford, MA, USA) on
reversed-phase support Waters C18 column (15 lm, 100 A˚
´
,
7.8 9 300 mm) with a linear gradients running from 30 to
55% [B] for 90 min for analogues I–VI, X–XIII from 40 to
65% [B] for 90 min for analogues VIII and IX, and from
45 to 65% [B] for 80 min for analogues VII and XIV, all at
a flow rate of 2.5 mL/min and UV detection at 226 and
254 nm. The appropriate fractions were pooled and
lyophilized. The purity of the peptides was controlled using
analytical HPLC (Waters Corporation, Milford, MA, USA)
with a Vydac C18 or Hypersil ODS C18 or Hypersil BDS
C18 column and matrix-assisted laser desorption/ionization
time of flight MALDI TOF mass spectroscopy (molecular
ion) was used to confirm the identity of the pure products.
According to both HPLC and MS, the purity of peptides
exceeded 98%. Their physicochemical properties are pre-
sented in Table 1.
Biological evaluation
Bioassay methods
Wistar rats were used in all experiments. Handling of the
experimental animals was done under supervision of the
Ethics Committee of the Academy of Sciences according to
§ 23 of the law of the Czech Republic no. 246/1992.
The uterotonic test was carried out in vitro on the strips of
rat uterus in the absence of magnesium ions (Holton 1948;
Munsick 1960; Slaninova´ 1987). Rats in induced estrus by the
injection of estrogen 48 h before the experiments were used.
After decapitation, the uterine horns were excised, longitu-
dinally cut, placed into a bathing chamber and hooked up to
recorder of contractions. The height of the single isometric
contraction of a uterine strip was measured. In principle,
cumulative dosing was applied in the experiments, i.e. doses
of standard (in the presence or absence of analogues) or of the
analogue were added successively to the uterus in the organ
bath in doubling concentrations and at 1 min intervals without
the fluid being changed until the maximal response (the
highest contraction) was obtained. The dose–response curves
were constructed. Synthetic oxytocin was used as standard.
Each new analogue was tested using uteri from 3 to 5 different
animals; the values in the Table are averages ± SEM.
Table 1 Physiochemical properties of peptides I–XIV
Analogue Formula Yielda (%) HPLC TR (min)
b [M ? H?]
Calculated Found
[cis-Apc2]AVP I C50H71N15O11S2 55.8 14.96
c 1121.5 1122.3
[Mpa1,cis-Apc2]AVP II C50H70N14O11S2 76.8 22.34 1106.4 1106.5
[cis-Apc2,Val4]AVP III C50H72N14O10S2 56.7 16.47
c 1091.5 1092.3
[Mpa1,cis-Apc2,Val4]AVP IV C50H71N13O10S2 82.8 18.80
c 1077.5 1078.3
[cis-Apc2,D-Arg8]VP V C50H71N15O11S2 41.8 19.24 1121.4 1122.9
[Mpa1,cis-Apc2,D-Arg8]VP VI C50H70N14O11S2 68.6 23.70 1106.4 1107.6
[Cpa1,cis-Apc2]AVP VII C55H78N14O11S2 57.9 25.07 1174.2 1175.4
Aca[cis-Apc2,Val4]AVP VIII C61H86N14O11S2 89.9 27.60
d 1254,5 1255.9
t-Bba[cis-Apc2,Val4]AVP IX C61H84N14O11S2 91.8 13.07
e 1252,3 1253.9
Hba[cis-Apc2,Val4]AVP X C57H76N14O12S2 90.5 19.96
d 1212,4 1213.9
Aba[cis-Apc2,Val4]AVP XI C57H76N14O12S2 92.4 19.96
d 1211,4 1212.8
[cis-Apc2]OT XII C47H72N12O11S2 43.0 20.10 1044.5 1045.4
[Mpa1,cis-Apc2]OT XIII C47H71N11O11S2 74.8 22.19 1029.4 1030.9
[Cpa1,cis-Apc2]OT XIV C52H89N11O11S2 61.6 27.05 1097.5 1098.3
[A] 0.1% aqueous trifluoroacetic acid (TFA), [B] acetonitrile : 0.1% aqueous TFA (80:20 v/v)
a Yields were calculated on the basis of the amino acid content of the resin
b Linear gradient from 20 to 80% of [B] in [A] for 30 min, Hypersil ODS C18 column
c Linear gradient from 20 to 80% of [B] in [A] for 20 min, Vydac C18 column
d Linear gradient from 30 to 90% of [B] in [A] for 30 min, Hypersil ODS C18 column
e Linear gradient from 60 to 90% of [B] in [A] for 60 min, Hypersil BDS C18 column
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The vasopressor test was performed using phenoxy-
benzamine-treated male rats (Dekanski 1952) under ure-
thane anesthesia. Arginine vasopressin was used as a
standard. Changes of the arterial blood pressure were reg-
istered. Dose (single administration into vena femoralis) –
response curves were constructed in the presence and
absence of an antagonist. The antagonist was administered
1 min prior to the administration of the standard. Each
analogue was tested in 3–5 independent experiments, the
values in the Table are averages ± SEM.
With agonists, the activity was expressed in IU/mg,
whereas with antagonists as pA2. The pA2 values represent
the negative logarithm to the base 10 of the average molar
concentration of an antagonist that reduces the response to
2 x units of the agonist to the response to x units of the
agonist (Slaninova´ 1987). The volume of distribution in the
in vivo experiments is arbitrarily taken as 67 ml/kg. The
responses to standard doses of oxytocin or vasopressin
were stable for several hours, without problems with
tachyphylaxis.
Tests to assess the antidiuretic property were conducted
on conscious male rats in a modified Burn test (Burn et al.
1950; Va´vra et al. 1974). In the standard manner with
hydrated rats, the animals having fasted for 16 h were
weighed and then given tap water through a stomach
catheter. The water load was 4% of the body weight.
Immediately after the water load, the tested substances (or
physiological saline as control) were administered subcu-
taneously at doses of 0.001–100 nmol/kg. The rats were
then placed in individual metabolic cages, and their urine
was collected over a 5 h period. The time t1/2 in which the
rats excreted half the water load was determined and then
plotted against the dose. As the dose–response curves were
not parallel, such doses were chosen for calculating the
compound’s potency which yield t1/2 equal to 60 min (the
so-called threshold doses equal to the value of t1/2 obtained
with the physiological solution) and t1/2 equal to 200 min.
On each day of the experiment, 21 rats divided into 5
groups of 4 or 5 animals were administered different doses
of different compounds; in an average each compound was
tested in 3–5 different doses, each dose being tested in 2 or
3 independent experiments (different days, different rats).
The results were thus expressed in IU/mg in comparison to
AVP (the value 450 IU/mg was taken for AVP for both t1/2
60 min and t1/2 200 min).
Binding affinity determination
Binding affinities to the human oxytocin receptor were
determined as described in (Fahrenholz et al. 1984), using
tritiated oxytocin from NEN Life Science, Boston, MA,
USA. In brief, a crude membrane fraction of HEK OTR
cells, i.e. HEK cells having stable expressed human OT
receptor (kindly donated by Dr. G. Gimpl (Gimpl et al.
1997), was incubated with [3H]OT (2 nM) and various
concentrations of peptides (0.1–10,000 nM) for 30 min at
35C. The total volume of the reaction mixture was
0.25 ml and the buffer used was 50 mM HEPES at pH 7.6
containing 10 mM MnCl2 and 1 mg/ml bovine serum
albumin. The reaction was terminated by quick filtration on
a Brandel cell harvester. Oxytocin was used as a control
and for determination of non-specific binding. Binding
affinities were expressed as Ki values calculated according
to the expression Ki = IC50/[(c3HOT/KdOT) ? 1], where
KdOT is taken as 1.8 nM (Soloff and Swartz 1974).
Results
Peptide synthesis and purification
Fourteen new neurohypophyseal hormone analogues were
obtained as crude products in about 41–92% yields. After
HPLC purification, their purity was better than 98% as
determined by analytical HPLC. The MALDI TOF mass
spectrometry confirmed identity of the purified peptides.
Their physicochemical characteristics are given in Table 1.
Biological activity
Pharmacological characteristics of the new analogues
together with those of AVP and some related peptides are
summarized in Table 2. The activities of the new com-
pounds were determined by the in vitro rat uterotonic test
in the absence of magnesium ions, the rat pressor test, and
by the antidiuretic assay using conscious rats, as described
in the ‘‘Biological evaluation’’ Section.
A comparison of the antidiuretic activities of the new
analogues with those published previously is complicated
by the fact that different methods were used for the activity
determination and that the dose–response curves of the
analogues and that of standard AVP have different slopes.
It is therefore necessary to provide two potency values, the
first resulting from comparison of the threshold doses of
AVP with those of the analogues (antidiuresis time t1/2
60 min) and the second originating from comparison of
doses giving an antidiuresis time of 200 min. The antidi-
uresis time (t1/2) corresponds to the time in which the rat
excretes half of the water load. For AVP, the activity has
arbitrarily been set to 465 IU/mg for both responses. None
of the new compounds exhibited diuretic or, in other
words, anti-antidiuretic activity
The new peptides (I–VI) showed weak antidiuretic
potency, about 10–465 times lower than that of AVP at the
threshold level (60 min). However, their activity was sig-
nificantly prolonged, they were about 2–19 fold more
622 A. Kwiatkowska et al.
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effective than AVP at the t1/2 level of 200 min, with the
exception of peptide V [cis-Apc2,D-Arg8]VP which turned
out to be a moderately potent agonist (about 43% of anti-
diuretic potency of AVP). The N-acylated AVP analogues
(VIII–XI) and peptide VII ([Cpa1,cis-Apc2]AVP) exhib-
ited either no (analogue XI) or only negligible (compounds
VII–X) antidiuretic activity. Among the oxytocin ana-
logues, the antidiuretic activity was estimated for one
compound (XIII) only and it was found inactive in this test.
Regarding the pressor activity, all the analogues modi-
fied at position 2 with cis-Apc were either weak (peptides
VII, XII) or moderate (compounds I–VI, XIII, XIV)
antagonists. The N-acylation of peptide III ([cis-Apc2,
Val4]AVP) eliminated its effect on blood pressure (ana-
logues VIII, IX, XI), with the exception of compound
X (Hba[cis-Apc2,Val4]AVP) which remained a weak
antagonist (pA2 * 6.4).
As can be seen in Table 2, in the uterotonic test most of
the analogues exhibited moderate (peptide I, pA2 = 7.47)
or high (compounds II–VII and XII–XIV, pA2 values
ranging from 7.89 to 8.46) anti-oxytocic potency. The
N-acylation had an inconsistent effect, in the case of pep-
tide VIII, the antioxytocin activity was strongly decreased,
in the case of peptides X and XI the antagonism was much
less decreased and surprisingly, acylation of the [cis-
Apc2,Val4]AVP peptide with 4-tert-butylbenzoic acid
transformed the high antiuterotonic activity into agonistic
one (analogue IX, 10.1 ± 3.8 IU/mg).
Binding affinity
The results of pharmacological tests on rats were supple-
mented by determination of the affinities of selected ana-
logues to human oxytocin receptors stably expressed on the
Table 2 Pharmacological properties of the new neurohypophyseal hormones analogues together with the values for AVP and some related
analogues
Analogue Activity*
Uterotonic in vitro no




60 min (200 min)
AVPa 17 412 465
OTa 450 5 5
[Mpa1]OTa 803 1.44 19
Atosiban, d[D-Tyr(Et)2,Thr4]OVTb,c 7.71 ± 0.05 pA2 = 6.14 ± 0.02 pA2 = 5.9
[Acc2]AVPd pA2 * 5.6 56.6 750–900 (*9,300)
[Mpa1,Acc2]AVPe pA2 * 5.6 (0.7 IU/mg) 17.2 ± 0.8 4,500 (50,000)
[Acc2,Val4]AVPe pA2 = 6.9 0.9 ± 0.30 2,300 (23,000)
[cis-Apc2]AVP I pA2 = 7.47 ± 0.30 pA2 = 6.73 10 (2,000)
[Mpa1,cis-Apc2]AVP II pA2 = 8.46 ± 0.20 pA2 = 7.41 45 (9,000)
[cis-Apc2,Val4]AVP III pA2 = 8.22 ± 0.11 pA2 = 6.85 15 (2,000)
[Mpa1,cis-Apc2,Val4]AVP IV pA2 = 8.40 ± 0.19 pA2 = 7.04 20 (4,500)
[cis-Apc2,D-Arg8]VP V pA2 = 7.98 ? 0.14 pA2 * 7.1 1 (200)
[Mpa1,cis-Apc2,D-Arg8]VP VI pA2 = 8.16 ? 0.02 pA2 * 7.1 5 (1,000)
[Cpa1,cis-Apc2]AVP VII pA2 = 7.85 ? 0.14 pA2 * 6.2 0.05 (1)
Aca[cis-Apc2,Val4]AVP VIII pA2 = 5.7 0 \0.01 (\0.5)
t-Bba[cis-Apc2,Val4]AVP IX 10.1 ? 3.8 IU/mg 0 \0.01 (\0.5)
Hba[cis-Apc2,Val4]AVP X pA2 = 7.61 pA2 * 6.4 \0.01 (\0.5)
Aba[cis-Apc2,Val4]AVP XI pA2 = 7.26 ? 0.40 0 0
[cis-Apc2]OT XII pA2 = 7.89 ? 0.07 pA2 * 5.75 ND
[Mpa1,cis-Apc2]OT XIII pA2 = 8.11 ? 0.18 pA2 * 6.0 0
[Cpa1,cis-Apc2]OT XIV pA2 = 7.97 ? 0.24 pA2 * 6.73 ND
* The values are given as averages ± SEM, n = 3–5
** 0 means no activity up to the dose of 0.15 mg/kg of experimental animal
*** Activity was estimated on the threshold level of activity 60 min and on the level of the 200 min activity (in parentheses); activity of AVP
taken as 465 IU/mg at both levels, ND no data available
Biological activities of the other analogues reported here as references are taken from the literature: aLebl (1987), bMelin et al. (1986), cManning
et al. (1995), dJastrze˛bska et al. (2003), eKowalczyk et al. (2004)
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HEK cells using tritiated oxytocin (Table 3). The results in
Table 3 show that two of the new analogues ([Mpa1,cis-
Apc2]AVP (II) and [Mpa1,cis-Apc2,Val4]AVP (IV)) had
higher affinities for the human OT receptor than the com-
monly used OT antagonist, Atosiban (Melin et al. 1986;
Manning et al. 1995). On the other hand, their counterparts
with Cys1 (peptides I, III) displayed the binding affinity
comparable with that of Atosiban (Ki = 110 ± 26 and
Ki = 88.8 ± 30.2, respectively).
Discussion
Our previous studies have demonstrated that modification
of the N-terminal part of the AVP molecule, especially by
reduction of conformational freedom, has a dramatic
impact on pharmacological activities of its analogues
(Kowalczyk et al. 2006; Derdowska et al. 2005; Kwiat-
kowska et al. 2009, 2010). In continuation of our research
that focuses on obtaining potent and selective neurohypo-
physeal hormone analogues with agonistic or antagonistic
properties, we now report on biological properties of a
series of new analogues modified at position 2 with cis-1-
amino-4-phenylcyclohexane-1-carboxylic acid.
The first group of compounds was designed by cis-Apc2
substitution of AVP and of some of its analogues having
additional modifications at positions 1, 4, and 8. As can be
seen in Table 2, this modification is sufficient to transform
the compounds from agonists into a moderately potent
blockers of oxytocic uterotonic activity (e.g. [cis-
Apc2]AVP, pA2 = 7.47). Moreover, combination of the
cis-Apc2 modification with Cpa1 or Mpa1 and/or Val4
substitution and/or inversion of configuration of Arg8 sig-
nificantly increased anti-oxytocic potency of the resulting
analogues (peptides II–VII). The most potent uterotonic
antagonists were obtained by deamination of position 1 of
the following peptides: [cis-Apc2]AVP, [cis-Apc2,Val4]
AVP, and [cis-Apc2,Val4,D-Arg8]AVP. It is worth
emphasizing that these compounds (II, IV and VI) with
anti-oxytocic potency pA2 of 8.46, 8.40 and 8.16, respec-
tively, turned out to be more potent antagonists than
Atosiban (pA2 = 7.71, Manning et al. 1995). The cis-Apc
amino acid differs from Acc residue used by us in a pre-
vious study in the presence of a phenyl moiety (Fig. 2a),
thus restoring the aromatic character of the side chain at
position 2. Peptides modified with Acc2, which were con-
sidered as models for the new compounds (I–VII) exhib-
ited only weak antiuterotonic activities, with the exception
of peptide [Cpa1,Acc2]AVP which displayed moderate
anti-oxytocic properties (pA2 = 7.33, Jastrze˛bska et al.
2003). It is noteworthy to mention that our previous results
showed that the presence of other than Tyr2 aromatic
amino acid residues at position 2, e.g. L-1-Nal enantiomers,
2-aminoindane-2-carboxylic acid, 3,3-diphenylalanine
enantiomers, and a-2-indanylglycine enantiomers (Der-
dowska et al. 2005; Kowalczyk et al. 2007; Kwiatkowska
et al. 2009, 2010) was favourable for generation of effec-
tive anti-oxytocic or antidiuretic agents. The results pre-
sented in this paper strongly support those previous
findings. Moreover, two of the new analogues, [Mpa1,cis-
Apc2]AVP and [Mpa1,cis-Apc2,Val4]AVP, exhibited a
much higher affinity for the human OT receptor (Ki val-
ues = 5.4–9.1 nM) than Atosiban (Table 3).
Regarding the antidiuretic tests, all new analogues
exhibited either very low (peptides I–IV, and VI, about
1–10% of the vasopressin activity) or only negligible
(compounds V and VII) activity at the threshold level
(60 min). However, their potency was significantly pro-
longed as can be seen from the activities calculated at the
antidiuresis half time level of 200 min, with the exception
of peptide VII. The degree of prolongation was in the case
of all analogues mentioned the same, i.e. ca 200 times. The
results presented in Table 2 show that two of the new
peptides, [Mpa1,cis-Apc2]AVP and [Mpa1,cis-Apc2,Val4]
AVP, were even 10–20-fold more effective than AVP at
the 200 min level. Also as far as the antidiuretic activity is
concerned, the structural difference between cis-Apc and
Acc modification plays an important role as our new cis-
Apc2-substituted peptides were only weak agonists at the
level of t1/2 60 min, while their counterparts with Acc
2
exhibited a high antidiuretic potency (Kowalczyk et al.
2004, Jastrze˛bska et al. 2003). It is interesting to note that
the combination of the above mentioned modifications (cis-
Apc or Acc) with additional substitution of position 1 with
1-mercaptocyclohexaneacetic acid (Cpa) resulted in ana-
logues with substantially reduced antidiuretic activity. We
have previously noticed this correlation in, for example, the
series of AVP analogues modified with 1-aminocyclo-
pentane-1-carboxylic acid (Kowalczyk et al. 2005) and 3,3-
diphenylalanine enantiomers (Kwiatkowska et al. 2009).
This finding suggests that Cpa modification in the N-ter-
minus of AVP with either bulky and sterically restricted or
Table 3 Binding affinities of Atosiban and AVP analogues (I–IV)
Analogue Ki (nM)
a
Atosiban, d[D-Tyr(Et)2,Thr4]OVTb 71.5 ± 21.2
[cis-Apc2]AVP I 110 ± 26
[Mpa1,cis-Apc2]AVP II 5.4 ± 1.2
[cis-Apc2,Val4]AVP III 88.8 ± 30.2
[Mpa1,cis-Apc2,Val4]AVP IV 9.1 ± 0.7
a Ki Concentration of peptide leading to half-maximal specific binding
deduced from competition experiments, experiments performed in
HEK cells
b The biological activity of the Atosiban is taken from the literature:
Reversi et al. (2005)
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just sterically restricted amino acid at position 2 is not
favourable for interaction with the receptor.
As far as the pressor test is concerned, the new ana-
logues (I–VI) were shown to be moderate antagonists of
the pressor response to AVP with the exception of peptide
VII which exhibited low antagonistic activity. As shown in
Table 2, the Cpa1 modification of the [cis-Apc2]AVP
molecule again resulted in a decreased activity.
In the uterotonic test, in general, cis-Apc2 substitution
resulted in compounds having high anti-oxytocin potency
(pA2 values ranging from 7.85 to 8.46). Even two of the
new peptides, [Mpa1, cis-Apc2]AVP and [Mpa1, cis-
Apc2,Val4]AVP, were more potent OT antagonists and
exhibited higher affinities for the human OT receptor than
Atosiban (the currently available tocolytic agent). How-
ever, they are also as non-selective as Atosiban, because of
their antidiuretic and antipressor activities.
To enhance the selectivity of our cis-Apc2 substituted
peptides, we tried two different approaches. First, N-acyl-
ation of the most active peptide III using 4 different acyl
groups (See Fig. 2b) was performed. This approach has
been successfully adopted in our laboratory to improve
antagonistic potency of bradykinin B2 antagonists in the rat
blood pressure assay (Lammek et al. 1990, 1991). The [cis-
Apc2,Val4]AVP peptide was chosen as a reference com-
pound for acylation because it showed a very interesting
pharmacological profile. This analogue exhibited a high
anti-oxytocic potency (pA2 = 8.22) and moderate pressor
antagonism (pA2 = 6.85), while its antidiuretic potency
was lower than that of AVP but with a significantly pro-
longed activity. For N-terminal acylation we decided to use
bulky groups with different chemical character since our
previous studies revealed that chemical character of the
acids used to modify the bradykinin antagonists was crucial
for the activity (Prahl et al. 1997; Trzeciak et al. 2000;
Labudda et al. 2007). The other approach involved intro-
duction of cis-Apc in position 2 of oxytocin and its ana-
logues [Mpa1]OT and [Cpa1]OT.
Acylation of the N-terminal part of [cis-Apc2,Val4]AVP
resulted in peptides VIII–XI with strikingly different
pharmacological properties as compared to that of the
reference analogue (Table 2). While the effect on pressor
activity and antidiuretic activity was consistent—in the
case of all four different acyl groups there was substantial
decrease of activity, regarding the oxytocic activity, the
effect was heterogenous. Two of the analogues with either
negative (X) or positive (XI) charge on the N-terminal acyl
group were moderate antagonists in the in vitro uterus test
(pA2 = 7.26 and 7.61, respectively) about 4 and 10 times
less potent than the mother compound III. The analog
modified with bulky 1-adamantanecarboxylic acid (Aca)
was shown to be a very weak anti-oxytocic agent
(pA2 = 5.7) and surprisingly, the peptide obtained by
acylation of the reference compound with 4-tert-butyl-
benzoic acid transformed its anti-oxytocic activity into an
agonistic one (10.1 ± 3.8 IU/mg). Thus a small difference
in the structure of the acyl group causes pronounced
change in the biological activity, see analogues VIII and
IX. Moreover, it should be emphasized that the presence of
a bulky acyl substituent at the N-terminus of [cis-Apc2,
Val4]AVP significantly improved selectivity of the result-
ing analogues and led to compound XI (Aba[cis-Apc2,
Val4]AVP) which is a moderately potent and exceptionally
selective anti-oxytocic agent. These results demonstrate
once more that conformation of the N-terminal part of
AVP analogues is crucial for their pharmacological
activity.
The next group of compounds studied consists of oxy-
tocin analogues: [cis-Apc2]OT (XII), [Mpa1, cis-Apc2]OT
(XIII) and [Cpa1, cis-Apc2]OT (XIV). The results pre-
sented in Table 2 show that introduction of cis-Apc in
position 2 of OT and some of its analogues resulted in
compounds having high antioxytocic potency (pA2 values
ranging from 7.89 to 8.11) comparable to their AVP
counterparts. In the pressor test and antidiuretic test the cis-
Apc2-substituted OT analogues have mostly much lower
activity than the of their AVP counterparts. Only analogue
XIV turned out to be moderate antagonists of vasopressin
pressor action. When comparing the properties of [Mpa1,
cis-Apc2]AVP and [Mpa1,cis-Apc2]OT (Table 2), they
both exhibited a high anti-oxytocic activity (pA2 = 8.46
and 8.11, respectively) but the oxytocin analogue was
distinctly more selective.
Conclusion
The results of this study demonstrate once more that con-
formational freedom and bulkiness of the N-terminal part
of the neurohypophyseal hormone molecules have a sig-
nificant impact on pharmacological activities. It has clearly
been shown that introduction of cis-Apc2 in position 2 of
either AVP or OT resulted in compounds with high anti-
oxytocin potency. Two of the new analogues, [Mpa1,cis-
Apc2]AVP (II) and [Mpa1,cis-Apc2,Val4]AVP (IV), were
exceptionally potent anti-uterotonic agents (pA2 = 8.46
and 8.40, respectively) and exhibited higher affinities for
the human OT receptor than Atosiban (Ki values 5.4 and
9.1 nM). Moreover, we have demonstrated for the first time
that N-terminal acylation of AVP analogue can improve its
selectivity. Using this approach, we obtained compound
Aba[cis-Apc2,Val4]AVP (XI) which turned out to be a
moderately potent and exceptionally selective OT antago-
nist (pA2 = 7.26). This combination of pharmacological
properties makes our new analogues promising candidates
for the development of potential tocolytic agents.
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In summary, our study provides new information on the
structure–activity relationship of neurohypophyseal hor-
mone analogues and can have an impact on designing
selectively acting anti-oxytocic agents. We are undertaking
further SAR studies on our cis-Apc2-substituted peptides
using NMR and theoretical molecular modelling methods
to provide structural rationale for the activity results.
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